glp 1 receptor agonists and kidney protection Potential kidney-protective other effects of GLP-1 GLP-1 receptor agonists and next-generation
Description
Afternoon fatigue and brain fog
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Semaglutide 2.4mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection
Next up: glucagon-like peptide 1 receptor agonists, known colloquially (and identified here) as GLPs
However, the molecular details of ago-allosterism remain elusive
This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient
